Shimadzu has released its new ICPMS-2030 Inductively Coupled Plasma Mass Spectrometer. It meets the requirements of the ICH Q3D guidelines for elemental impurities in pharmaceutical products. The ICPMS-2030 satisfies these requirements with ppt level high sensitivity. This is achieved by the newly developed collision cell and the optimized internal structure. During the ICPMS-2030 European Launch Tour ("Critical Mass Tour") starting March 2016, the ICPMS-2030 can be seen at several exhibitions.
For more details please visit www.shimadzu.eu
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.